Schroder Investment Management Group Buys 235,863 Shares of IDEXX Laboratories, Inc. $IDXX

Schroder Investment Management Group boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 295.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 315,785 shares of the company’s stock after buying an additional 235,863 shares during the quarter. Schroder Investment Management Group’s holdings in IDEXX Laboratories were worth $169,368,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC bought a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $29,000. Ameritas Advisory Services LLC bought a new position in IDEXX Laboratories in the second quarter worth $36,000. Elevation Point Wealth Partners LLC acquired a new stake in IDEXX Laboratories during the second quarter worth $36,000. WPG Advisers LLC bought a new stake in IDEXX Laboratories in the 1st quarter valued at $37,000. Finally, NewSquare Capital LLC raised its stake in shares of IDEXX Laboratories by 87.5% in the 2nd quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock valued at $40,000 after buying an additional 35 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.98% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on IDXX shares. BTIG Research upped their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Piper Sandler reiterated a “neutral” rating and set a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $730.50.

IDEXX Laboratories Stock Down 0.4%

NASDAQ IDXX opened at $753.05 on Friday. The firm has a market cap of $60.13 billion, a PE ratio of 62.70, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The stock’s 50 day simple moving average is $666.95 and its 200 day simple moving average is $605.72. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.08. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.